triamcinolone acetonide, ranibizumab, neovascular age-related macular degeneration
Conditions
Interventions
Two groups:Group A (combination therapy) received treatments comprised of intravitreal triamcinolone (novartis) 4mg in 0.1 mL followed by intravitreal ranibizumab (novartis) 0.5 mg in 0.05 mL. Group B
Sponsors
Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong
Eligibility
Sex/Gender
All
Age
50 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients with active subfoveal CNV of all types (including predominantly classic, minimally classic, occult, and retinal angiomatous proliferation) secondary to AMD; 2. Age beyond 50 years old; 3. Only one eye are suffering from CNV; 4. Best-corrected visual acuity (BCVA) between 20/32 and 20/320 measured on Early Treatment of Diabetic Retinopathy Study (ETDRS) charts; 5. Lesions do not exceed 12 disk areas; 6. No more than 50% of the lesions could be occupied by subretinal hemorrhage; 7. Pseudophakic eyes; 8. Patients can give consent.
Exclusion criteria
Exclusion criteria: 1. Eyes with subfoveal fibrosis or atrophy, retinal pigment epithelial tear involving the macula, or subretinal hemorrhage involving the center of the fovea (>50% of the total CNV area); 2. Eyes have been treated for AMD with intraocular anti-VEGF therapy or are previous treatment with verteporfin photodynamic therapy or laser photocoagulation within the past 3 months; 3. Intraocular surgery within the past 2 months or likely to be performed during the study period; 4. Documented diabetic retinopathy, uncontrolled glaucoma, and CNV not related to AMD; 5. History or presence of intraocular inflammation or infection; 6. History of glaucoma and on more than one topical medication; 7. History of glaucoma filtering surgery in the study eye; 8. Family history of glaucoma.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence and severity of ocular adverse events and visual acuity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Total number of treatments required;change in central macular thickness (CMT);changes in aqueous concentrations of specific angiogenic and inflammatory cytokines;change in the size of choroidal neovascular membrane in fluorescein angiography and adverse events including retinal pigment epithelial tear;submacular hemorrhage;elevation of intraocular pressure;endophthalmitis; | — |
Countries
China
Contacts
Public ContactDr Marten BRELéN
Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong
Outcome results
None listed